QURE UNIQURE NV

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications officer, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in October:

  • SVB Leerink CybeRx Series: Rare & Genetics, October 1, 2020



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings in the afternoon on Thursday, October 1, 2020.



  • Jefferies Virtual Gene Therapy/Editing Summit, October 1 – 2, 2020



    • A fireside chat with research analyst Suji Jeong, Ph.D. will take place on Friday, October 2, 2020 from 9:00 – 9:25 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the morning on Friday, October 2, 2020.



  • Chardan Virtual 4th Annual Genetic Medicines Conference, October 5 – 6, 2020



    • A fireside chat with research analyst Gbola Amusa will take place on Tuesday, October 6, 2020 from 1:00 – 1:25 p.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the afternoon on Tuesday, October 6, 2020.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts:
   
FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
  



EN
30/09/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Closing of Upsized Public Offering and Full Exercise...

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of th...

September 29, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Pricing of Upsized $300 Million Public Offering

uniQure Announces Pricing of Upsized $300 Million Public Offering LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the ...

September 26, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces $200 Million Proposed Public Offering

uniQure Announces $200 Million Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Refinancing of Existing $50 Million Debt and Securin...

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding ~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ approval ~ ~ Transaction provides financial flexibility and improves cost of capital ~ LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing trans...

September 24, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Positive Topline Results from Pivotal Phase I/II Stu...

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 m...

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch